Health products giant Johnson & Johnson said it will buy U.S.-Swiss medical device maker Synthes Inc. for $21.3 billion, greatly increasing its share of the market for surgical trauma equipment and orthopedic implants.
Sage-N Research, Inc. announced a new API toolkit for developers of proteomics data analysis software. The toolkit will enable software developers to add the power and sensitivity of SORCERER analyses to their existing software packages.
Harvard Apparatus has introduced a new line of OEM Syringe Pumps designed for specialized solutions for a variety of fluid handling applications to meet fluidics research requirements.
KemPharm, Inc. announced that KP106 will be formulated and developed in an oral film dosage form pursuant to an exclusive collaboration agreement with MonoSol Rx relating to the development, commercialization and manufacture of KP106.
Eppendorf and the world-renowned journal Science are now accepting applications for the 2011 Eppendorf & Science Prize for Neurobiology. The Eppendorf & Science Prize for Neurobiology is an annual international research prize of US$ 25,000.
The largest study ever to examine the association of dietary fats and prostate cancer risk has found what's good for the heart may not be good for the prostate.
A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study has found.
Kuros Biosurgery AG, announced that KUR-113 met the primary efficacy endpoint in a 200 patient Phase 2b clinical trial designed to assess its efficacy and safety in open tibial shaft fracture patients.
Horizon Pharma, Inc. announced that the U.S. Food and Drug Administration has approved DUEXIS, a novel tablet formulation containing a fixed-dose combination of ibuprofen and famotidine.
Pain Therapeutics Inc. reported clinical study results that may indicate its pain drug candidate Remoxy is more difficult to abuse than OxyContin. The company said patients with a history of abusing painkillers did not enjoy Remoxy as much as OxyContin.
It's now up to a Spartanburg County judge to decide how much a Johnson & Johnson subsidiary should pay South Carolina for deceptive marketing of an antipsychotic drug. If the judge agrees with attorneys for the state, it could be in the billions of dollars.
Absorption Systems announced the results of another study demonstrating the power of the company’s CellPort Technologies to predict the potential for pharmacokinetic drug-drug interactions.
The ProteaseArrest family of protease inhibitor cocktails are unique ready-to-use liquid format cocktails that offer immediate >98% inhibition of harmful proteases.
AMSBIO has announced the launch of Alvetex, a cell culture scaffold that enables genuine 3D cell culture to be grown routinely and cost-effectively.
Merck and Sanofi Pasteur announced the initiation of a Phase 3 clinical program to evaluate the safety and immunogenicity of an investigational pediatric hexavalent combination vaccine.